InDex Pharmaceuticals is an immunology focused biopharmaceutical company. We have developed two assets from our in-house, proprietary technology platform:
Currently in a European multicenter Phase III trial in severe treatment refractory Ulcerative Colitis
A development candidate for treatment resistant pulmonary inflammation.
We are dedicated to discovering and developing treatments exclusively in disease states where there is a high unmet medical need. In the case of Kappaproct, there is today no alternative pharmaceutical treatment for severe ulcerative colitis patients who have failed all other medical treatments and whose only option is surgical removal of the colon (colectomy) leading to colostomy and a poor quality of life. Kappaproct has received an Orphan Drug Designation from the European Medicines Agency (EMA) for "active Ulcerative Colitis" and can expect a fast track process.
We are also dedicated to personalized medicine. InDex is developing a Companion Diagnostic (CDx) to Kappaproct that will allow selection of those patients most likely to benefit from treatment. The CDx is in development and is being pre-validated in our ongoing clinical study.
InDex has developed DiBiCol, a diagnostic test that can discriminate between Crohn’s disease and Ulcerative Colitis, the two major forms of inflammatory bowel disease (IBD). DiBiCol received market approval in Sweden in 2009 and has since been used in routine clinical practice at a large number of clinics. As from June, 2012 the DiBiCol Sampling Kit is CE marked.
It is our conviction that our focus on indications with high unmet medical needs complimented with our commitment to personalized medicine will create significant value for all our stakeholders: patients, caregivers, payers and InDex Pharmaceuticals shareholders.